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Open Forum Infectious Diseases
MAJOR ARTICLE

Mark H. Wilcox,1 Galia Rahav,2 Erik R. Dubberke,3 Lori Gabryelski,4 Kerrie Davies,1 Claire Berry,1 Karen Eves,4 Misoo C. Ellison,4 Dalya Guris,4 and
Mary Beth Dorr4
1

Leeds Teaching Hospitals & University of Leeds, Leeds, West Yorkshire, UK; 2Sheba Medical Center, Tel Hashomer, & Sackler Medical School, Tel Aviv University, Israel; 3Washington University
School of Medicine, St Louis, Missouri; 4Merck & Co., Inc., Kenilworth, New Jersey

Background. The optimum diagnostic test method for Clostridioides difficile infection (CDI) remains controversial due to variation in accuracy in identifying true CDI. This post hoc analysis examined the impact of CDI diagnostic testing methodology on
efficacy outcomes in phase 3 MODIFY I/II trials.
Methods. In MODIFY I/II (NCT01241552/NCT01513239), participants received bezlotoxumab (10 mg/kg) or placebo during
anti-CDI treatment for primary/recurrent CDI (rCDI). Using MODIFY I/II pooled data, initial clinical cure (ICC) and rCDI were
assessed in participants diagnosed at baseline using direct detection methods (enzyme immunoassay [EIA]/cell cytotoxicity assay
[CCA]) or indirect methods to determine toxin-producing ability (toxin gene polymerase chain reaction [tgPCR]/toxigenic culture).
Results. Of 1554 participants who received bezlotoxumab or placebo in MODIFY I/II, 781 (50.3%) and 773 (49.7%) were diagnosed by tgPCR/toxigenic culture and toxin EIA/CCA, respectively. Participants diagnosed by toxin EIA/CCA were more likely to
be inpatients, older, and have severe CDI. In bezlotoxumab recipients, ICC rates were slightly higher in the toxin EIA/CCA subgroup
(81.7%) vs tgPCR/toxigenic culture (78.4%). Bezlotoxumab significantly reduced the rCDI rate vs placebo in both subgroups; however, the magnitude of reduction was substantially larger in participants diagnosed by toxin EIA/CCA (relative difference, –46.6%)
vs tgPCR/toxigenic culture (–29.1%). In bezlotoxumab recipients, the rCDI rate was lower in the toxin EIA/CCA subgroup (17.6%)
vs tgPCR/toxigenic culture (23.6%; absolute difference, –6.0%; 95% confidence interval, –12.4 to 0.3; relative difference, –25.4%).
Conclusions. Diagnostic tests that detect fecal C. difficile toxins are of fundamental importance to accurately diagnosing CDI,
including in clinical trial design, ensuring that therapeutic efficacy is not underestimated.
Keywords. diagnosis; diarrhea; toxin; treatment outcome.
Clostridioides difficile is a Gram-positive, spore-forming anaerobe that resides naturally in the large intestine of up to 15%
of the adult population [1]. Disruption of the normal intestinal
microbiota, most commonly due to treatment with broad-spectrum antibiotics, can lead to the overgrowth of C. difficile [2, 3].
The subsequent production of C. difficile toxin A and B causes
colonic inflammation, resulting in mild to severe diarrhea and
abdominal pain and more serious manifestations, including fulminant colitis, severe leukocytosis, and death [3, 4].
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There has been a marked increase in the incidence and severity of C. difficile infection (CDI) in recent years [5–7].
Although antibiotic treatment for primary CDI is often successful, it has been reported that ~25% of individuals experience recurrent CDI after completing initial antibiotic therapy
[8, 9]. After the first recurrent episode, individuals have a 38%–
45% probability of a second recurrence, with increasing risk
with further recurrences [10, 11].
Bezlotoxumab (MK-6072), a fully human monoclonal antibody that binds to C. difficile toxin B, is indicated to prevent
recurrence of CDI (rCDI) in at-risk adults receiving antibacterial drug treatment for primary or recurrent CDI [12]. In the
MODIFY I/II phase 3 trials, a single infusion of bezlotoxumab
administered with or without actoxumab (a monoclonal antibody against C. difficile toxin A) resulted in a significantly lower
rCDI rate over 12 weeks compared with placebo [13].
The study design of the MODIFY trials, including the definition of CDI and diagnostic methods used, was based on the 2010
Infectious Diseases Society of America/Society for Healthcare
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Influence of Diagnostic Method on Outcomes in
Phase 3 Clinical Trials of Bezlotoxumab for the Prevention
of Recurrent Clostridioides difficile Infection: A Post Hoc
Analysis of MODIFY I/II

METHODS
Study Design

MODIFY I/II (NCT01241552/NCT01513239) were randomized, double-blind, placebo-controlled, multicenter, phase 3
trials conducted between November 1, 2011, and May 22,
2015, at 322 sites in 30 countries. Full trial details have previously been published [13]. Briefly, adults receiving a 10–14day regimen of antibacterial drug treatment (metronidazole,
vancomycin, or fidaxomicin) for primary CDI or rCDI were
2 • ofid • Wilcox et al

randomized to receive a single infusion of bezlotoxumab
(10 mg/kg of body weight) or actoxumab (10 mg/kg; MODIFY I
only) or bezlotoxumab plus actoxumab (10 mg/kg each) or
placebo (0.9% saline). CDI was defined as ≥3 unformed bowel
movements (types 5 to 7 on the Bristol Stool Scale [20] in
24 hours), with a positive stool test for toxigenic C. difficile.
In this post hoc analysis of pooled data from MODIFY I/II
trials (including only participants who received bezlotoxumab
or placebo), a number of end points were investigated through
12 weeks in 2 subgroups: participants diagnosed at baseline via
an indirect method (toxin gene PCR [tgPCR]/toxigenic culture) and participants diagnosed at baseline via a direct toxin
detection method (toxin EIA/CCA). Different populations
were included in the diagnostic subgroups; the toxin EIA/CCA
subgroup only included toxin-positive participants, whereas
the tgPCR/toxigenic culture subgroup likely included both
toxin-positive and toxin-negative participants. All permitted
commercial test kits had a labeled specificity of ≥94% with the
capacity to detect the presence of C. difficile toxin B (toxin EIA
kits) or its cognate tcdB gene (PCR kits).
End Points

The main efficacy end points included initial clinical cure (ICC)
and rCDI. ICC was defined as no diarrhea during the 2 consecutive days after completion of ≤16 calendar days of anti-CDI
treatment. rCDI was defined as a new episode of diarrhea associated with a positive stool test for toxigenic C. difficile in participants who had achieved the ICC of the baseline CDI episode;
the diagnostic methods used for testing the stool of recurrent
diarrhea episodes were preferably the same as those used for
trial eligibility.
Other efficacy end points included sustained cure (defined as clinical cure of the initial CDI episode and no rCDI
through 12-week follow-up), diarrhea recurrence (a new episode of diarrhea in participants who had achieved ICC of the
baseline CDI episode, regardless of whether a stool test for
toxigenic C. difficile was positive, negative, or not performed),
rehospitalization (the occurrence of 30-day all-cause and CDIassociated hospital readmissions), fecal microbiota transplant
(FMT; the receipt of an FMT at any time during the study),
and all-cause mortality (the occurrence of death within 30 and
90 days after randomization).
Statistical Analyses

The modified intent-to-treat (mITT) population was used for
ICC estimations and included all randomized participants in
the overall population of the MODIFY I/II trials who received
the study infusion, had a positive baseline stool test for toxigenic
C. difficile, and received anti-CDI treatment within 1 day of the
study infusion. mITT participants who achieved ICC of the
baseline CDI episode were included in rCDI and diarrhea recurrence estimations (clinical cure population). Rehospitalization
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Epidemiology of America (IDSA/SHEA) CDI guidelines [14].
Due to the absence of an optimal CDI diagnostic test at the
time, these guidelines included several test methods in their recommendations. Stool culture followed by the identification of
a toxigenic isolate (known as toxigenic culture) and cell cytotoxicity assay (CCA) testing were considered the gold standard;
however, these methods were deemed impractical for routine
diagnosis due to a long turnaround time [14]. Enzyme immunoassay (EIA) was considered to be most important clinically,
but was limited by a lack of sensitivity [14]. Polymerase chain
reaction (PCR) testing was described as a rapid, sensitive, and
specific method, but more evidence was required to evaluate its
utilization in routine diagnostic testing [14]. Consequently, a
range of test methods was permitted for use by the local laboratories to diagnose CDI in participants enrolled in MODIFY I/II.
Since the 2010 IDSA/SHEA CDI guidelines were published,
further research has clearly shown that the presence of toxigenic
C. difficile alone (ie, toxin-negative) is not always indicative of
clinical disease. Indeed, 4%–29% of hospitalized individuals are
asymptomatic carriers of toxigenic C. difficile [1]. Furthermore,
multiple studies have correlated the presence of C. difficile
toxins with clinical outcome, showing that individuals who
have C. difficile toxin present in their stool (ie, toxin-positive)
experience higher rCDI and mortality rates compared with individuals who have toxigenic C. difficile bacteria, but no toxin,
in their stool (ie, toxin-negative) [15, 16]. These findings suggest that toxigenic PCR and culture methods, which detect
C. difficile bacteria regardless of toxin production, may not reflect true CDI.
Previous research has suggested that PCR-diagnosed individuals may be less likely to respond to CDI treatment compared
with those diagnosed using a direct toxin-based test [17–19]. As
both direct and indirect test methods were used to diagnose CDI
in MODIFY I/II, it is possible that the dilution of treatmentresponsive participants with non-treatment-responsive “false
CDI” participants may have led to the underestimation of the
therapeutic efficacy of bezlotoxumab. This post hoc analysis
examined this hypothesis, with the aim to determine if the
CDI diagnostic testing methodology used in MODIFY I/II
had an impact on efficacy outcomes in participants receiving
bezlotoxumab or placebo.

Assay Interference Experiment

An assay interference experiment was performed to determine if the reduced rate of rCDI observed in bezlotoxumabtreated participants diagnosed via toxin EIA/CCA compared
with those diagnosed via tgPCR/toxigenic culture was a true
result, rather than bezlotoxumab rendering diagnostic toxin
EIA or CCA results falsely negative because of binding to free
toxins present in fecal samples. Further detail is available in the
Supplementary Data.
RESULTS
Participants

The integrated mITT population from MODIFY I/II consisted
of 1554 participants, of whom 781 received bezlotoxumab
and 773 received placebo. Baseline demographic and clinical characteristics were generally similar between treatment
groups [13]. In total, 781 (50.3%) participants were diagnosed by tgPCR/toxigenic culture: 399 (out of 781, 51.1%)
participants in the bezlotoxumab group and 382 (out of
773, 49.4%) participants in the placebo group. Overall, 773
(49.7%) participants were diagnosed by toxin EIA/CCA: 382
(out of 781, 48.9%) participants in the bezlotoxumab group
and 391 (out of 773, 50.6%) participants in the placebo group
(Table 1).
A toxin EIA kit was the most commonly used diagnostic test
at baseline (48.7% of participants), followed by tgPCR (44.7%),
toxigenic culture (5.6%), and CCA (1.1%) (Supplementary
Table 1). Direct toxin detection methods (toxin EIA/CCA)
were more common in Europe, whereas indirect toxin detection methods (tgPCR/toxigenic culture) were more common
in North America (Table 1). Overall, the use of different test
methods was balanced across treatment groups (Table 1).
In both treatment groups, a higher proportion of participants
diagnosed via toxin EIA/CCA prematurely discontinued from
the study (bezlotoxumab, 17.0%; placebo, 18.7%) vs tgPCR/toxigenic culture (bezlotoxumab, 11.5%; placebo, 13.9%). The most
frequent reasons for discontinuation were death and participant
withdrawal (Supplementary Table 2).

Compared with participants diagnosed via tgPCR/toxigenic
culture, a higher proportion of participants diagnosed via toxin
EIA/CCA were inpatients at the time of randomization, were
older, and had severe CDI (Zar score ≥ 2) or ≥1 of 5 prespecified
risk factors for rCDI (Table 1).
Initial Clinical Cure

ICC rates were slightly lower in participants diagnosed via
tgPCR/toxigenic culture (bezlotoxumab, 78.4%; placebo, 77.7%)
vs toxin EIA/CCA (bezlotoxumab, 81.7%; placebo, 82.9%), with
a similar rate between treatment groups (Figure 1).
CDI Recurrence

Compared with placebo, bezlotoxumab significantly reduced
the rCDI rate regardless of diagnostic method, with an absolute difference of –15.4% (95% CI, –22.0% to –8.7%) and –9.7%
(95% CI, –16.8% to –2.5%) in the toxin EIA/CCA and tgPCR/
toxigenic culture subgroups, respectively (Figure 2). Among
bezlotoxumab-treated participants, the rCDI rate tended to be
lower in participants diagnosed by toxin EIA/CCA (17.6%) vs
tgPCR/toxigenic culture (23.6%; absolute difference, –6.0%;
95% CI, –12.4% to 0.3%; relative difference –25.4%). In contrast, rCDI was ~33% in the placebo group regardless of diagnostic method (Figure 2). The relative reduction in rCDI rate
for bezlotoxumab- vs placebo-treated participants was higher
at 46.6% for toxin EIA/CCA vs 29.1% for tgPCR/toxigenic culture (Figure 3).
CDI Recurrence Stratified by Baseline Demographic and Clinical
Characteristic Subgroups

Across the majority of baseline demographic and clinical characteristic subgroups in the treatment and placebo arms, rCDI
rates were lower in participants diagnosed with toxin EIA/CCA
(Figure 3A) vs tgPCR/toxigenic culture (Figure 3B). Absolute
differences in rCDI between the bezlotoxumab and placebo
groups were also larger in participants diagnosed by toxin EIA/
CCA in these subgroups; however, the 95% CIs of the difference
included 0 in some subgroups (Figure 3). In participants with
primary CDI (ie, no CDI in the past 6 months), the absolute
reduction in rCDI rate was greater in those diagnosed by toxin
EIA/CCA (13.5%) compared with tgPCR/toxigenic culture
(5.3%; 95% CIs included 0). A similar trend was observed for
inpatients, metronidazole-treated participants, and European
participants (Figure 3).
A sensitivity analysis was also conducted that investigated
the proportion of participants who experienced diarrhea recurrence irrespective of an association with C. difficile. Here,
a similar trend was observed, with lower diarrhea recurrence
rates in the toxin EIA/CCA subgroup vs the tgPCR/toxigenic
culture subgroup (Supplementary Table 3). Additionally, a
higher proportion of participants diagnosed via toxin EIA/
CCA achieved sustained cure vs tgPCR/toxigenic culture
(Supplementary Table 4).
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was estimated in mITT participants who were hospitalized at
the time of randomization. Mortality was estimated using the
“all patients as treated” population, which included all randomized participants who received the study infusion.
Initial and sustained cure rates, as well as observed rCDI
and diarrhea recurrence rates, are presented, along with rate
differences between the bezlotoxumab and placebo groups
and their 95% confidence intervals (CIs). The 95% CIs are
based on the Miettinen and Nurminen method [21]. Other
outcomes, including rehospitalization, FMT, and mortality
during the 12-week follow-up period, are summarized descriptively using the frequency and percentage for each treatment group.

Table 1.

Baseline Demographics and Clinical Characteristics in the mITT Population by Treatment Group and Diagnostic Method
Bezlotoxumab
a

EIA + CCA,No. (%)
Participants in population

PCR + Culture,No. (%)

a

EIA + CCA,No. (%)

PCR + Culture,No.a (%)

382

399

391

382

299 (78.3)

231 (57.9)

307 (78.5)

213 (55.8)

Female

212 (55.5)

230 (57.6)

235 (60.1)

214 (56.0)

Mean age (SD), y

65.7 (16.8)

58.2 (18.4)

65.4 (17.9)

61.5 (16.7)

  Median

69

60

68

63

  Range

21–100

18–97

19–98

18–97

Age ≥65 y

226 (59.2)

164 (41.1)

230 (58.8)

175 (45.8)

≥1 CDI episodes in past 6 mo

93 (24.3)

123 (30.8)

114 (29.2)

105 (27.5)

≥2 previous CDI episodes ever

41 (10.9)

59 (15.0)

61 (15.8)

65 (17.6)

Severe CDI (Zar score ≥ 2)b

72 (18.8)

50 (12.5)

77 (19.7)

48 (12.6)

Immunocompromisedc
Antibiotic used during ADT

81 (21.2)

97 (24.3)

72 (18.4)

81 (21.2)

131 (34.3)

115 (28.8)

142 (36.3)

134 (35.1)

Antibiotic used after ADT

131 (34.3)

115 (28.8)

110 (28.1)

114 (29.8)

At least 1 of the 5 predefined risk factorse

304 (79.6)

288 (72.2)

313 (80.1)

270 (70.7)
146 (38.2)

Charlson Comorbidity Index ≥3

170 (44.5)

149 (37.3)

157 (40.2)

Albumin <2.5 g/dL

63 (16.5)

38 (9.5)

58 (14.8)

45 (11.8)

Renal impairmentf

68 (17.8)

55 (13.8)

53 (13.6)

57 (14.9)

Hepatic impairmentg

30 (7.9)

19 (4.8)

24 (6.1)

20 (5.2)

Antibiotic drug treatment for CDI
Metronidazole

191 (50.0)

188 (47.1)

193 (49.4)

181 (47.4)

Vancomycin

176 (46.1)

196 (49.1)

187 (47.8)

186 (48.7)

Fidaxomicin

15 (3.9)

15 (3.8)

11 (2.8)

15 (3.9)

PCR ribotypeh
Participants with a positive culture

237

253

250

236

027, 078, or 244 strain

58 (24.5)

44 (17.4)

71 (28.4)

44 (18.6)

027 strain

54 (22.8)

35 (13.8)

64 (25.6)

36 (15.3)

Regioni
Africa
Asia-Pacific
Europe

0 (0.0)

5 (1.3)

0 (0.0)

2 (0.5)

57 (14.9)

22 (5.5)

53 (13.6)

24 (6.3)
106 (27.7)

205 (53.7)

108 (27.1)

187 (47.8)

Latin America

21 (5.5)

9 (2.3)

26 (6.6)

9 (2.4)

North America

99 (25.9)

255 (63.9)

125 (32.0)

241 (63.1)

Abbreviations: ADT, antibacterial drug treatment; ALT, alanine aminotransferase; CDI, Clostridioides difficile infection; CCA, cell cytotoxicity assay; EIA, enzyme immunoassay; mITT, modified
intent-to-treat; PCR, polymerase chain reaction; ULN, upper limit of normal; WBC, white blood cell.
a

No. represents the number of participants in the subgroup analysis population meeting the criteria for the end point.

b

Based on the following: (1) age >60 years (1 point), (2) body temperature >38.3°C (>100°F; 1 point), (3) albumin level <2.5 g/dL (1 point), (4) peripheral WBC count >15 000 cells/mm3 within
48 hours (1 point), (5) endoscopic evidence of pseudomembranous colitis (2 points), and (6) treatment in an intensive care unit (2 points).

c

Defined on the basis of a subject’s medical history or use of immunosuppressive therapy.

d

Systemic antibiotic other than ADT given to treat CDI.

e

Predefined risk factors include CDI history in the past 6 months, severe CDI at baseline (per Zar score), age ≥65 years, having a hypervirulent strain (027, 078, or 244 ribotypes) at baseline,
and immunocompromised.
f

Renal impairment defined as serum creatinine ≥1.5 mg/dL.

g

Hepatic impairment defined by 2 or more of the following: (a) albumin ≤3.1 g/dL, (b) ALT ≥2× ULN, (c) total bilirubin ≥1.3× ULN, or (d) mild, moderate, or severe liver disease (as reported
on the Charlson Comorbidity Index).
h

Denominator is participants in the mITT population with a positive culture.

i

Africa includes South Africa. Asia-Pacific includes Australia, Japan, Korea, New Zealand, and Taiwan. Latin America includes Argentina, Brazil, Chile, Colombia, and Mexico. Europe includes
Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Poland, Portugal, the Russian Federation, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.
North America includes Canada and the United States.

Assay Interference Experiment

Compared with control samples incubated without bezlotoxumab,
incubation of fecal samples with the median observed stool concentration of bezlotoxumab (528.0 ng/mL) (Supplementary
Data) did not change diagnostic toxin EIA or CCA results
(Supplementary Table 5). Compared with control samples, incubation of samples with higher bezlotoxumab concentrations (10×
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median, 100× median) had no effect on diagnostic EIA results,
but changed the diagnostic result from positive to negative in
some samples tested by CCA (Supplementary Table 5).
Other Outcomes

In participants in both treatment groups who were inpatients
at the time of randomization, the all-cause rehospitalization
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Inpatient

Placebo
a

100
90
80

Difference (95% CI)a:
–1.2 (–6.6 to 4.2)
81.7

82.9

312
382

324
391

Difference (95% CI)a:
0.7 (–5.1 to 6.5)
78.4

77.7

313
399

297
382

70
60
50
40
30
20
10
0
Toxin EIA + CCA

tgPCR + toxigenic culture
Diagnostic test method

Figure 1. Proportion of participants with initial clinical cure (mITT population). aBased on the Miettinen and Nurminen method. Abbreviations: CCA, cell cytotoxicity assay;
CI, confidence interval; EIA, enzyme immunoassay; mITT, modified intent-to-treat; tgPCR, toxin gene polymerase chain reaction.

rate was higher in those diagnosed with tgPCR/toxigenic culture vs toxin EIA/CCA (Table 2). In contrast, in both treatment groups, there was a trend for higher CDI-associated
rehospitalization rates in participants diagnosed with toxin
EIA/CCA vs tgPCR/toxigenic culture (Table 2). Similarly,
there was a trend for higher mortality in participants diagnosed with toxin EIA/CCA vs tgPCR/toxigenic culture in both
treatment groups (Table 2). Compared with the bezlotoxumab
group, a higher proportion of placebo-treated participants
had an FMT procedure during the follow-up period, regardless of diagnostic method (Table 2).

DISCUSSION

CDI diagnosis is based on clinical presentation and laboratory
testing, although the methodology for the latter remains controversial. Increasing evidence supports the higher predictive
value of toxin detection rather than the presence of a strain with
the capacity to produce toxin (ie, toxigenic culture or toxin gene
detection) [14, 23]. As several different test methods were used
to diagnose CDI in MODIFY I/II, it was important to establish
if this had an effect on the measured efficacy of bezlotoxumab.
In these 2 trials, almost equal proportions of participants
in the bezlotoxumab and placebo groups were diagnosed via

Bezlotoxumab
Placebo

% participants with rCDI
(MODIFY I and II pooled data)

40

Difference (95% CI)a:
–15.4 (–22.0 to –8.7)

Difference (95% CI)a:
–9.7 (–16.8 to –2.5)
33.3

33.0

35
30

23.6

25
20

17.6

15
10
5

55
312

107
324

74
313

99
297

0
Toxin EIA + CCA

tgPCR + toxigenic culture
Diagnostic test method

Figure 2. Proportion of participants with rCDI (clinical cure population). aBased on the Miettinen and Nurminen method. Abbreviations: CCA, cell cytotoxicity assay; CI, confidence interval; EIA, enzyme immunoassay; rCDI, recurrent Clostridioides difficile infection; tgPCR, toxin gene polymerase chain reaction.
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% participants with initial clinical cure
(MODIFY I and II pooled data)

Bezlotoxumab
Placebo

A
Subgroup

Bezlotoxumab,

Placebo,

No./na (%)

No./na (%)

Rate difference
Absolute, %

Relative, %

55/312 (17.6) 107/324 (33.0)

–15.4

–46.6

32/183 (17.5)

75/188 (39.9)

–22.4

–56.1

33/234 (14.1)

63/228 (27.6)

–13.5

–48.9

1 CDI episode in past 6 mo

22/76 (28.9)

43/95 (45.3)

–16.3

–33.3

2 previous CDI episodes ever

13/35 (37.1)

28/53 (52.8)

–15.7

–29.7

Immunocompromised

10/67 (14.9)

16/58 (27.6)

–12.7

–46.0

Severe CDI; Zar score 2

7/48 (14.6)

17/56 (30.4)

–15.8

–52.0

027, 078, or 244 strain

12/47 (25.5)

21/56 (37.5)

–12.0

–32.0

027 strain

12/45 (26.7)

20/50 (40.0)

–13.3

–33.3

46/247 (18.6)

95/256 (37.1)

–18.5

–49.9

Inpatient

38/242 (15.7)

77/248 (31.0)

–15.3

–49.4

Outpatient

17/70 (24.3)

30/76 (39.5)

–15.2

–38.5

Metronidazole

24/157 (15.3)

49/163 (30.1)

–14.8

–46.5

30/142 (21.1)

53/153 (34.6)

–13.5

–39.0

All participants
Risk factors for recurrence

1 risk factor
Stratification variables

Vancomycin
Geographic region
Asia-Pacific

7/48 (14.6)

15/45 (33.3)

–18.8

–56.2

Europe

29/167 (17.4)

50/154 (32.5)

–15.1

–46.5

North America

17/79 (21.5)

35/103 (34.0)

–12.5

–36.8

–40

–30

–20

–10

0

Bezlotoxumab better

B

10

20

Placebo better

Bezlotoxumab,

Placebo,

No./na (%)

No./na (%)

Absolute, %

Relative, %

74/313 (23.6)

99/297 (33.3)

–9.7

–29.1

28/128 (21.9)

52/134 (38.8)

–16.9

–43.6

42/214 (19.6)

51/205 (24.9)

–5.3

–21.3

1 CDI episode in past 6 mo

32/95 (33.7)

47/87 (54.0)

–20.3

–37.6

2 previous CDI episodes ever

16/46 (34.8)

25/50 (50.0)

–15.2

–30.4

Immunocompromised

16/76 (21.1)

26/64 (40.6)

–19.6

–48.0

Severe CDI; Zar score 2

6/32 (17.6)

11/33 (33.3)

–15.7

–47.1

027, 078, or 244 strain

10/31 (32.3)

16/34 (47.1)

–14.8

–31.4

027 strain

9/26 (34.6)

14/29 (48.3)

–13.7

–28.4

54/224 (24.1)

79/212 (37.3)

–13.2

–35.4

Inpatient

35/175 (20.0)

43/158 (27.2)

–7.2

–26.5

Outpatient

39/138 (28.3)

56/139 (40.3)

–12.0

–29.8

Metronidazole

32/150 (21.3)

36/141 (25.5)

–4.2

–16.5

37/150 (24.7)

61/144 (42.4)

–17.7

–41.7

Subgroup

All participants

Rate difference

Risk factors for recurrence
65 y of age
No CDI in past 6 mo

1 risk factor
Stratification variables

Vancomycin
Geographic region
Europe
North America

18/91 (19.8)

21/84 (25.0)

–5.2

–20.8

52/198 (26.3)

71/186 (38.2)

–11.9

–31.2

–40

–20

–30

Bezlotoxumab better

–10

0

10

20

Placebo better

Figure 3. The proportion of participants who experienced rCDI according to subgroup (clinical cure population; MODIFY I and II pooled data). A, Subgroup results for
participants diagnosed by toxin EIA or CCA. B, Subgroup results for participants diagnosed by tgPCR or toxigenic culture. aNo. represents the number of participants in the
subgroup analysis population meeting the criteria for the end point; n represents the number of participants within the subgroup. Abbreviations: CCA, cell cytotoxicity assay;
CDI, Clostridioides difficile infection; EIA, enzyme immunoassay; rCDI, recurrent Clostridioides difficile infection; tgPCR, toxin gene polymerase chain reaction.

tgPCR/toxigenic culture vs toxin EIA/CCA, which reflects the
diagnostic variability at the time of trial design [14].
Our post hoc analysis demonstrates that bezlotoxumab was
associated with clinically meaningful reductions in rCDI rates
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compared with placebo, regardless of the diagnostic method
used; however, the magnitude of reduction of rCDI associated
with bezlotoxumab was substantially higher among participants diagnosed by toxin EIA/CCA vs tgPCR/toxigenic culture.
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65 y of age
No CDI in past 6 mo

Table 2.

Proportion of Participants Who Experienced Rehospitalization, FMT, or Mortality (MODIFY I and II Pooled Data)
Bezlotoxumab
a

b

Placebo
a

b

a

b

Toxin EIA + CCA, No./n (%)

tgPCR + Culture, No./n (%)

Toxin EIA + CCA, No./n (%)

tgPCR + Culture,a No./nb (%)

63/299 (21.1)

60/231 (26.0)

80/307 (26.1)

60/213 (28.2)

16/299 (5.4)

11/231 (4.8)

39/307 (12.7)

19/213 (8.9)

2/382 (0.5)

5/399 (1.3)

13/391 (3.3)

10/382 (2.6)

Rehospitalizationc
Associated with CDId
Received an FMTe
Mortalityf
30-d mortality

17/382 (4.5)

10/404 (2.5)

15/394 (3.8)

12/387 (3.1)

90-d mortality

35/382 (9.2)

19/404 (4.7)

35/394 (8.9)

24/387 (6.2)

Abbreviations: CCA, cell cytotoxicity assay; CDI, Clostridioides difficile infection; EIA, enzyme immunoassay; FMT, fecal microbiota transplant; mITT, modified intent-to-treat; rCDI, recurrent
Clostridioides difficile infection; tgPCR, toxin gene polymerase chain reaction.
a

Diagnostic subgroups are based on the test method used to diagnose the baseline CDI episode.

b

No. represents the number of participants in the subgroup analysis population meeting the criteria for the end point; n represents the number of participants within the subgroup.

c

mITT population who were inpatients at the time of randomization.

d
CDI-associated rehospitalization was defined as a 30-day readmission based on ≥1 of the following: readmission that occurred within 5 days after onset of a new CDI episode, onset of a
new CDI episode during readmission, or the inclusion of terms synonymous with CDI, rCDI, or pseudomembranous colitis in the discharge diagnosis, as recorded on the trial case report
form [22].
e

mITT population.

f

All participants as treated population.

Notably, a similar trend in rCDI reduction was also observed
across subgroup and sensitivity analyses. Furthermore, results
from the assay interference experiment suggest that the trend
in rCDI reduction is a true result rather than an artefact present
due to falsely negative toxin EIA/CCA results, as exposure of
fecal samples to physiological levels of bezlotoxumab generally
had no effect on the results derived by either diagnostic test.
As the bezlotoxumab stock had to be diluted to meet the fecal
concentrations required, the change in diagnostic CCA results
from positive to negative observed in some samples may have
been due to a dilution effect.
ICC rates also tended to be slightly higher in participants
diagnosed with toxin EIA/CCA compared with tgPCR/toxigenic culture, which was evident in both the bezlotoxumab and
placebo groups. This is plausibly because participants diagnosed
via toxin EIA/CCA were more likely to have CDI-related diarrhea, and thus to have a better response to CDI treatment compared with participants diagnosed by tgPCR/toxigenic culture
(who may not have had true CDI) [16]. The larger reduction
in rCDI could be partly explained by the difference in baseline
characteristics, as there were more inpatients, older participants, and severe CDI cases in the toxin EIA/CCA subgroup vs
the tgPCR/toxigenic culture subgroup at baseline; however, this
is unlikely, as a lower reduction in rCDI in older participants
with severe CDI would be expected.
In addition, a higher proportion of participants diagnosed via
toxin EIA/CCA, vs tgPCR/toxigenic culture, prematurely discontinued from the study. There was also a trend for higher mortality
rates in participants diagnosed by toxin EIA/CCA compared
with tgPCR/toxigenic culture. Similarly, this could be partly influenced by the difference in baseline participant characteristics.
Our findings are consistent with previous post hoc clinical
trial analyses, which have also suggested that CDI treatment is

less efficacious in PCR-diagnosed individuals compared with
those diagnosed using a toxin-based test [17–19]. Furthermore,
our findings are consistent with recent data suggesting a correlation between the presence of fecal C. difficile toxins and true
CDI. Planche and colleagues previously reported that mortality
rates were significantly higher in individuals who were confirmed to be toxin-positive, compared with those who were
toxin-negative, but had a positive toxigenic culture test result
[15]. Similarly, in another study of hospitalized patients with
suspected CDI, virtually all CDI-related complications and
deaths occurred in toxin-positive individuals [16].
It has been speculated that exclusive reliance on diagnostic
tests that only detect toxigenic C. difficile strains may lead to
over-reporting of CDI cases. Indeed, a number of studies have
shown that performing tgPCR instead of toxin EIA or CCA
to diagnose CDI can lead to increases of ~50% in CDI rates
[24–26]. In another study, the use of tgPCR vs toxin EIA was
associated with inadequacies in the performance tool used to
assess institutional CDI rates. This was due to a failure in the
risk-adjustment approach, designed to correct for the use of
different diagnostic test methods between institutions, which
could lead to false reporting of high CDI rates in some institutions [27].
Notably, almost half of the participants enrolled in
MODIFY I/II were not diagnosed using a toxin-based test;
therefore, some of these participants may have had an alternate
cause of diarrhea. This likely explains why bezlotoxumab was
associated with a lower magnitude of reduction in rCDI rate in
participants diagnosed by tgPCR/toxigenic culture.
Although recent treatment guidelines acknowledge the diagnostic concern regarding molecular tests that only detect the
presence of C. difficile toxin genes, the choice of tgPCR and
toxin-based testing is still included in their recommendations
Diagnostic Method and MODIFY I/II Outcomes • ofid • 7
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